| Product Unit Size | Cost | Quantity | Stock |
|---|
Imatinib is an anticancer chemotherapeutic compound that inhibits Abl, c-Kit, and PDGFR; it is used clinically to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL). In cellular assays, imatinib accelerates erythroblast differentiation and inhibits melanogenesis.
| Cas No. | 220127-57-1 |
|---|---|
| Purity | ≥98% |
| Formula | C29H31N7O • CH3SO3H |
| Formula Wt. | 589.718 |
| Chemical Name | methanesulfonic acid; 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| IUPAC Name | methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3- ylpyrimidin-2-yl)amino]phenyl]benzamide |
| Synonym | STI-571, STˆ571, Gleevec |
| Melting Point | 226C |
| Solubility | Ethanol (0.2 mg/ml), DMSO (10 mg/ml), Dimethyl Formamide, PBS (2 mg/mL) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Wang Y, Zhao Y, Liu L, et al. Inhibitory effects of imatinib mesylate on human epidermal melanocytes. Clin Exp Dermatol. 2014 Mar;39(2):202-8. PMID: 24479586.
D'allard D, Gay J, Descarpentries C, et al. Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One. 2013 Apr 23;8(4):e60961. PMID: 23637779.
Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 2003 Feb;4(2):75-85. PMID: 12573349.